Liraglutide
FDA-approved
Brand names: Saxenda, Victoza
Liraglutide is an earlier, once-daily GLP-1-only agonist — approved for both diabetes (Victoza) and weight management (Saxenda) — with a boxed warning for thyroid C-cell tumors seen in rodent studies.
Label reference — not medical advice
Static FDA prescribing-information dosing schedule, shown for reference only. This is not personalized to you and is not a recommendation — always follow what your prescriber directed.
| Phase | Dose | Frequency |
|---|---|---|
| Starting dose | 0.6 mg | once daily |
| Titration step 2 | 1.2 mg | once daily |
| Titration step 3 | 1.8 mg | once daily |
| Titration step 4 | 2.4 mg | once daily |
| Maintenance | 3 mg | once daily |
Side effects
Common
Nausea, Diarrhea, Vomiting, Constipation, Injection site reactions, Headache
Serious (less common)
Pancreatitis, Gallbladder disease, Thyroid C-cell tumors (boxed warning), Acute kidney injury
When to contact a clinician
- A lump or swelling in the neck, hoarseness, or trouble swallowing (thyroid tumor boxed warning)
- Severe, persistent abdominal pain (possible pancreatitis) — seek care immediately
- Signs of severe allergic reaction (swelling, trouble breathing)
News & trials
Live news feed coming soon. In the meantime, see the Learn hub for the latest cited articles.